[go: up one dir, main page]

MX2012003424A - Tratamiento y prevencion de infeccion por el virus de inmunodeficiencia humana. - Google Patents

Tratamiento y prevencion de infeccion por el virus de inmunodeficiencia humana.

Info

Publication number
MX2012003424A
MX2012003424A MX2012003424A MX2012003424A MX2012003424A MX 2012003424 A MX2012003424 A MX 2012003424A MX 2012003424 A MX2012003424 A MX 2012003424A MX 2012003424 A MX2012003424 A MX 2012003424A MX 2012003424 A MX2012003424 A MX 2012003424A
Authority
MX
Mexico
Prior art keywords
treatment
infection
prevention
human immunodeficiency
immunodeficiency viruses
Prior art date
Application number
MX2012003424A
Other languages
English (en)
Inventor
Lieven Elvire Colette Baert
Guenter Kraus
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of MX2012003424A publication Critical patent/MX2012003424A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nanotechnology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se refiere al tratamiento a largo plazo de infección por VIH administrando de manera intermitente una formulación parenteral que comprende brecanavir a intervalos de tiempo relativamente largos; esta invención se refiere además a composiciones farmacéuticas para administración parenteral, que comprenden micro o nanopartículas de brecanavir, suspendidas en un vehículo farmacéuticamente aceptable acuoso, para el tratamiento y profilaxis de infección por VIH.
MX2012003424A 2009-09-22 2010-09-22 Tratamiento y prevencion de infeccion por el virus de inmunodeficiencia humana. MX2012003424A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09170916 2009-09-22
PCT/EP2010/063930 WO2011036159A2 (en) 2009-09-22 2010-09-22 Treatment and prevention of hiv infection

Publications (1)

Publication Number Publication Date
MX2012003424A true MX2012003424A (es) 2012-05-08

Family

ID=41466671

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003424A MX2012003424A (es) 2009-09-22 2010-09-22 Tratamiento y prevencion de infeccion por el virus de inmunodeficiencia humana.

Country Status (16)

Country Link
US (1) US20120201868A1 (es)
EP (1) EP2480220B1 (es)
JP (1) JP5897465B2 (es)
KR (2) KR101811314B1 (es)
CN (1) CN102573815B (es)
AU (1) AU2010299959B2 (es)
BR (1) BR112012006345A2 (es)
CA (1) CA2774750C (es)
DK (1) DK2480220T3 (es)
ES (1) ES2530941T3 (es)
HR (1) HRP20150192T1 (es)
MX (1) MX2012003424A (es)
PL (1) PL2480220T3 (es)
RU (1) RU2569058C2 (es)
WO (1) WO2011036159A2 (es)
ZA (1) ZA201202070B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3155587A1 (en) * 2019-10-01 2021-04-08 Viiv Healthcare Company Method for treating hiv with cabotegravir and rilpivirine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
AR031520A1 (es) 1999-06-11 2003-09-24 Vertex Pharma Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
US7220768B2 (en) * 2003-02-11 2007-05-22 Wyeth Holdings Corp. Isoxazole-containing thiourea inhibitors useful for treatment of varicella zoster virus
RS52821B2 (sr) * 2006-01-20 2021-07-30 Janssen Sciences Ireland Unlimited Co Dugotrajno tretiranje hiv-infekcije sa tcm278
ES2437331T3 (es) * 2007-07-12 2014-01-10 Janssen R&D Ireland Forma cristalina de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo

Also Published As

Publication number Publication date
CN102573815A (zh) 2012-07-11
BR112012006345A2 (pt) 2020-08-11
PL2480220T3 (pl) 2015-10-30
DK2480220T3 (en) 2015-02-23
CA2774750C (en) 2017-11-28
HRP20150192T1 (hr) 2015-04-10
HK1174256A1 (en) 2013-06-07
ZA201202070B (en) 2013-08-28
AU2010299959A1 (en) 2012-03-01
KR20170141825A (ko) 2017-12-26
US20120201868A1 (en) 2012-08-09
CA2774750A1 (en) 2011-03-31
AU2010299959B2 (en) 2016-07-21
RU2012116070A (ru) 2013-10-27
CN102573815B (zh) 2015-09-30
JP2013505224A (ja) 2013-02-14
KR101845811B1 (ko) 2018-05-18
EP2480220B1 (en) 2014-11-19
RU2569058C2 (ru) 2015-11-20
WO2011036159A2 (en) 2011-03-31
JP5897465B2 (ja) 2016-03-30
ES2530941T3 (es) 2015-03-09
EP2480220A2 (en) 2012-08-01
KR20120093850A (ko) 2012-08-23
WO2011036159A3 (en) 2011-11-24
KR101811314B1 (ko) 2017-12-26

Similar Documents

Publication Publication Date Title
PH12016500389B1 (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EA201590862A1 (ru) Фармацевтические композиции
MX346193B (es) Composiciones farmaceuticas.
MX2017007814A (es) Compuesto de carbamoilpiridona policiclicos y su uso farmaceutico.
DOP2011000343A (es) Derivados de piridina tieno [2,3-b] como inhibidores de replicacion viral
MX2012007410A (es) Compuestos antivirales novedosos.
MX2013005478A (es) Compuestos heterociclicos condensados antivirales.
NZ629996A (en) 2’- substituted carba-nucleoside analogs for antiviral treatment
SI2709613T1 (en) Procedures for the treatment of HCV
PH12015502539B1 (en) Cenicriviroc compositions and methods of making and using the same
MX2017012393A (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
NZ741957A (en) Therapeutic compositions for treatment of human immunodeficiency virus
CL2017000714A1 (es) Composiciones farmacéuticas de acción prolongada
MX2012003424A (es) Tratamiento y prevencion de infeccion por el virus de inmunodeficiencia humana.

Legal Events

Date Code Title Description
FG Grant or registration